From 8f41004a61967b297944f0b73c9845cace1fb196 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Wed, 18 Mar 2026 11:19:46 +0000 Subject: [PATCH] extract: 2026-02-01-glp1-patent-cliff-generics-global-competition Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA> --- ...t cost impact inflationary through 2035.md | 12 ++++++++++++ ...atent-cliff-generics-global-competition.md | 19 ++++++++++++++++++- 2 files changed, 30 insertions(+), 1 deletion(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 2dee64667..8c58ca33b 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -83,6 +83,18 @@ Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plus manufacturer-funded lifestyle support represents the first major policy attempt to address the chronic-use cost structure. The Medicare GLP-1 Bridge (July 2026) provides immediate price relief while full model architecture is built, indicating urgency around cost containment. + +### Additional Evidence (challenge) +*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-18* + +International generic competition beginning in 2026 will compress prices faster than the existing claim assumes. Canada's semaglutide patents expired January 4, 2026, with Sandoz, Apotex, and Teva filing immediately. Brazil opens to generics March 2026 (Biomm + Biocon). China has 17+ Phase 3 generic candidates targeting $40-$50/month pricing. India patents expire March 2026. Even before US generics (2031-2033), international price arbitrage and compounding pharmacy pressure will drive US prices below $100/month by 2030. At $50-100/month, GLP-1s become unambiguously cost-effective under any payment model, potentially shifting the inflection point (where volume growth no longer offsets price compression) significantly earlier than 2035. + + +### Additional Evidence (extend) +*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-18* + +Oral Wegovy launched January 2026 at $149-$299/month (vs $1,349/month for injectable), with Medicare deal at $245/month. This represents 82-89% price compression from injectable to oral formulation within the branded market, before any generic competition. The oral formulation shift accelerates the price decline trajectory independent of patent expiry. + --- Relevant Notes: diff --git a/inbox/archive/2026-02-01-glp1-patent-cliff-generics-global-competition.md b/inbox/archive/2026-02-01-glp1-patent-cliff-generics-global-competition.md index bbeeccda9..ccd4fac65 100644 --- a/inbox/archive/2026-02-01-glp1-patent-cliff-generics-global-competition.md +++ b/inbox/archive/2026-02-01-glp1-patent-cliff-generics-global-competition.md @@ -7,9 +7,13 @@ date: 2026-02-01 domain: health secondary_domains: [internet-finance] format: article -status: unprocessed +status: enrichment priority: medium tags: [glp-1, generics, patent-cliff, global-competition, drug-pricing, market-structure] +processed_by: vida +processed_date: 2026-03-18 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -50,3 +54,16 @@ Overview of the GLP-1 generic competition landscape as patents begin expiring in PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: Price trajectory is the key variable the existing claim depends on — if prices decline faster than assumed, the "inflationary through 2035" conclusion may be wrong EXTRACTION HINT: Focus on the price trajectory and its implications for cost-effectiveness under different payment models, especially the international competition pressure + + +## Key Facts +- Semaglutide patents extend to 2031-2032 in US and Europe +- Canada became first G7 nation with semaglutide patent expiry on January 4, 2026 +- Sandoz, Apotex, and Teva filed for Canadian generic semaglutide immediately after patent expiry +- Brazil generic competition opens March 2026 with Biomm + Biocon (India) preparing generic semaglutide +- China has 17+ generic semaglutide candidates in Phase 3 trials +- India semaglutide patent expirations scheduled March 2026 +- Oral Wegovy launched January 2026 at $149-$299/month +- Medicare negotiated oral Wegovy price: $245/month +- Injectable Wegovy list price: $1,349/month +- China/India projected generic semaglutide pricing: $40-$50/month